Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes

McCubrey, James A.2022-02-042022-02-042019-090887-6924http://hdl.handle.net/10342/9631en-USgene mutationsmyelodysplastic syndromes (MDS)azacitidine and lenalidomideResponse of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific GenesArticle10.1038/s41375-019-0416-x